| Bioactivity | Hetrombopag is a potent thrombopoietin receptor agonist. Hetrombopag is efficacious and well tolerated with a manageable safety profile. Hetrombopag has the potential for the research of immune thrombocytopenia[1]. | ||||||||||||
| Name | Hetrombopag | ||||||||||||
| CAS | 2114365-78-3 | ||||||||||||
| Formula | C25H22N4O5 | ||||||||||||
| Molar Mass | 458.47 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Mei H, et al. A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. J Hematol Oncol. 2021;14(1):37. |
Hetrombopag
CAS: 2114365-78-3 F: C25H22N4O5 W: 458.47
Hetrombopag is a potent thrombopoietin receptor agonist. Hetrombopag is efficacious and well tolerated with a manageable
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.